Precipio Announces Q1-2025 Shareholder Update Call

Conference Call to be held on May 15th, 2025 at 5:00 PM EST NEW HAVEN, [...]

Precipio Announces Q4 and year-end 2024 Shareholder Update Call

Conference Call to be held on March 31st, 2025 at 5:00 PM EST NEW HAVEN, [...]

Precipio Achieves Key Q4-2024 Financial Goals: Positive Adjusted EBITDA and Positive Cash Flow (unaudited)

Both metrics demonstrate the ability to achieve financial independence NEW HAVEN, CT, Globenewswire – (February [...]

Precipio grants senior management performance-based awards instead of traditional time-vested ESOPs

These options vest when PRPO stock price is 5x the exercise price NEW HAVEN, CT, [...]

Precipio Announces Q3-2024 Shareholder Update Call

Conference Call to be held on November 18, 2024, at 5:00 PM EST NEW HAVEN, [...]

Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping

The unique assay enables laboratories to provide clinicians with more informed treatment decisions for their [...]

Precipio Announces Employee Stock Option Plan Repricing

Management lays out rationale and impact to shareholders below NEW HAVEN, CT, (September 6th, 2024) – [...]

Precipio Announces Q2-2024 Shareholder Update Call

Conference Call to be held on August 19, 2024 at 5:00 PM EST NEW HAVEN, [...]

Precipio Reports $0.3M cash generated by operations (unaudited) in Q2-2024, as the company advances towards breakeven

Company’s continued growth and improved cash position alleviates the need for capital raise in the [...]

Precipio Reports $4.4M for Q2-2024 (unaudited) Revenues, a leap of 30% from Q1-2024

Pathology Revenues in June exceed breakeven target and continue growth trend NEW HAVEN, CT, Globenewswire [...]